Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia

Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US... Oncol Ther (2019) 7:67–81 https://doi.org/10.1007/s40487-019-0094-x ORIGINAL RESEARCH Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia . . . . L. Elise Horvath Walsh Alex Rider James Piercy James Pike . . Samuel Wilson Bhavik J. Pandya Bruno C. Medeiros Received: January 16, 2019 / Published online: April 26, 2019 The Author(s) 2019 Methods: Physicians in the USA captured ABSTRACT demographics, current AML treatment and symptoms for 82 AML patients who completed Introduction: There is limited understanding the Functional Assessment of Cancer Therapy- concerning the health-related quality of life Leukemia (FACT-Leu), 5-Dimension EuroQol (HRQoL) in acute myeloid leukemia (AML) Questionnaire (EQ-5D-3L) and Cancer Treat- patients. Due to an overlap of symptoms, it can ment Satisfaction Questionnaire (CTSQ). Effect be difficult to separate disease versus treatment- size (ES) and clinically meaningful differences related effects. Study objectives were to under- between AML subgroups were assessed, as was stand the impact of factors that might influence the impact of disagreement between patients patients’ HRQoL, assess the degree of concor- and physicians regarding symptom recognition. dance in symptom reporting by patients and Results: Clinically meaningful lower overall physicians, and assess the impact of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia

Download PDF
15 pages

Loading next page...
 
/lp/springer-journals/real-world-impact-of-physician-and-patient-discordance-on-health-bvyaLHgV19
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-0094-x
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2019) 7:67–81 https://doi.org/10.1007/s40487-019-0094-x ORIGINAL RESEARCH Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia . . . . L. Elise Horvath Walsh Alex Rider James Piercy James Pike . . Samuel Wilson Bhavik J. Pandya Bruno C. Medeiros Received: January 16, 2019 / Published online: April 26, 2019 The Author(s) 2019 Methods: Physicians in the USA captured ABSTRACT demographics, current AML treatment and symptoms for 82 AML patients who completed Introduction: There is limited understanding the Functional Assessment of Cancer Therapy- concerning the health-related quality of life Leukemia (FACT-Leu), 5-Dimension EuroQol (HRQoL) in acute myeloid leukemia (AML) Questionnaire (EQ-5D-3L) and Cancer Treat- patients. Due to an overlap of symptoms, it can ment Satisfaction Questionnaire (CTSQ). Effect be difficult to separate disease versus treatment- size (ES) and clinically meaningful differences related effects. Study objectives were to under- between AML subgroups were assessed, as was stand the impact of factors that might influence the impact of disagreement between patients patients’ HRQoL, assess the degree of concor- and physicians regarding symptom recognition. dance in symptom reporting by patients and Results: Clinically meaningful lower overall physicians, and assess the impact of

Journal

Oncology and Therapy – Springer Journals

Published: Apr 26, 2019

References

  • Cancer statistics, 2018
    Siegel, RL; Miller, KD; Jemal, A
  • Acute myeloid leukemia
    Döhner, H; Weisdorf, DJ; Bloomfield, CD
  • Acute myeloid leukemia in the older adults
    Almeida, AM; Ramos, F
  • Survival for older patients with acute myeloid leukemia: a population-based study
    Oran, B; Weisdorf, DJ
  • Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
    Schlenk, RF; Döhner, K; Krauter, J
  • Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
    Abbas, S; Lugthart, S; Kavelaars, FG
  • IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Marcucci, G; Maharry, K; Wu, YZ
  • IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication
    Paschka, P; Schlenk, RF; Gaidzik, VI
  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
    Perl, AE; Altman, JK; Cortes, J
  • Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
    Buchner, T; Berdel, WE; Schoch, C
  • Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
    Kantarjian, H; Ravandi, F; O’Brien, S
  • Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
    Roboz, GJ; Wissa, U; Ritchie, EK
  • Comorbidity, physical function, and quality of life in older adults with acute myeloid leukemia
    Storey, S; Gray, TF; Bryant, AL
  • Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life
    Redaelli, A; Stephens, JM; Brandt, S; Botteman, MF; Pashos, CL
  • Real-world physician and patient behaviour across countries: disease-Specific Programmes—a means to understand
    Anderson, P; Benford, M; Harris, N; Karavali, M; Piercy, J
  • Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme
    Babineaux, SM; Curtis, B; Holbrook, T; Milligan, G; Piercy, J
  • Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015
    Higgins, V; Piercy, J; Roughley, A
  • Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire
    Cella, D; Jensen, SE; Webster, K
  • Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy
    Kantarjian, HM; Mamolo, CM; Gambacorti-Passerini, C
  • Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia
    Trask, PC; Cella, D; Besson, N; Kelly, V; Masszi, T; Kim, DW
  • EuroQol—a new facility for the measurement of health-related quality of life
    EuroQol, G
  • Modeling valuations for EuroQol health states
    Dolan, P
  • Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D
    Walters, SJ; Brazier, JE
  • Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
    Pickard, AS; Neary, MP; Cella, D
  • Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing
    Abetz, L; Coombs, JH; Keininger, DL
  • Reliability and validity of the Cancer Therapy Satisfaction Questionnaire in lung cancer
    Cheung, K; Mol, M; Visser, S; Oudsten, BL; Stricker, BH; Aerts, JG
  • The measurement of observer agreement for categorical data
    Landis, JR; Koch, GG
  • The impact of remission status on patients’ experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data
    Kayastha, N; Wolf, SP; Locke, SC; Samsa, GP; El-Jawahri, A; LeBlanc, TW
  • Systematic review of health state utility values for acute myeloid leukemia
    Forsythe, A; Brandt, PS; Dolph, M; Patel, S; Rabe, APJ; Tremblay, G
  • Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia
    Kurosawa, S; Yamaguchi, T; Mori, T
  • Health-related quality of life of patients with acute myeloid leukemia: a systematic literature review
    Korol, EE; Wang, S; Johnston, K; Ravandi-Kashani, F; Levis, M; Nooten, F
  • The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review
    Atkinson, T; Ryan, SJ; Bennett, AV
  • Perceptions of prognosis and treatment risk in older patients with acute myeloid leukemia
    El-Jawahri, A